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UromodulinSeveral renal diseases involve mutations in the gene encoding uromodulin, the predominant
protein in urine. We investigated the intracellular processing of wild-type uromodulin, and three
mutants: p.V93_G97del/ins AASC; C155R; and C150S. A renal biopsy from a patient harboring the
C155R mutation revealed intracellular protein accumulation. Wild-type uromodulin was efﬁciently
trafﬁcked to the cell surface in transfected tsA 201 cells, whereas the mutants were partially
retained within the cell, and incompletely processed. Atomic force microscopy imaging revealed
that the intracellular mutant proteins contained ﬁbrillar structures similar to urinary uromodulin.
We suggest that premature intracellular polymerization underlies the pathology of uromodulin
diseases.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Uromodulin is the most abundant protein in human urine. A
variety of functions have been ascribed to it, including modulation
of water permeability of the nephron [1], prevention of bacterial
colonization [2] and inhibition of urinary tract stone formation
[3]. Mutations in UMOD, the gene that elaborates uromodulin,
cause a number of allelic autosomal dominant renal diseases,
including Familial Juvenile Hyperuricemic Nephropathy (FJHN)
[4] and Medullary Cystic Kidney Disease (MCKD2) [5]. By a
poorly-understood mechanism these diseases result in hyperurice-
mia, progressive tubulointerstitial ﬁbrosis, a urinary concentrating
defect and eventual renal failure requiring renal replacement ther-
apy. Transplantation is curative. Interestingly, the UMOD locus has
also been identiﬁed as the most signiﬁcant in a genome-wide
association study of all forms of chronic kidney disease (CKD) [6].
It has been suggested that increased expression levels associatedwith common variants at the UMOD locus might be the basis for
this association [7].
It has been reported that some mutant forms of UMOD that
result in autosomal dominant renal disease are retained within
the endoplasmic reticulum (ER) in vitro, leading to a reduction in
uromodulin secretion relative to wild-type (WT) [8–10]. This intra-
cellular retention has also been seen in a transgenic mouse model
of UMOD disease [11]. However, the structure of the secreted or
retained protein has not previously been assessed. Here we used
atomic force microscopy (AFM) imaging to investigate the struc-
tures of WT uromodulin, and of three disease-associated mutants:
C155R (previously unreported), p.V93_G97del/ins AASC (Indel) [8]
and C150S [12]. Our study provides the ﬁrst evidence of structural
defects resulting from pathological UMOD mutations, and suggests
that UMOD pathology results from the premature intracellular
polymerization of the mutant protein.
2. Materials and methods
2.1. Isolation of uromodulin from urine
With Ethical Committee approval (NRES 08-H0306-62), urine
from three healthy human volunteers was centrifuged at
10000g for 10 min, and the resulting pellet was resuspended in
HEPES-buffered saline. Samples of urine and protein pellets were
analyzed by SDS–polyacrylamide gel electrophoresis (SDS–PAGE),
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using a sheep polyclonal anti-human uromodulin antibody (R&D
Systems).
2.2. Cell culture
tsA 201 cells (a sub-clone of human embryonic kidney 293 cells
stably expressing the SV40 large T-antigen) were grown in Dul-
becco’s modiﬁed Eagle’s medium supplemented with 10% (v/v)
fetal bovine serum, 100 lg/ml of streptomycin and 100 units/ml
of penicillin in an atmosphere of 5% CO2/air.
2.3. Constructs
WT human uromodulin, and the Indel (c.278_289del
TCTGCCCCGAAGinsCCGCCTCCT; p.V93_G97del/ins AASC), C155R
and C150S mutants, each bearing an N-terminal hemagglutinin
(HA) epitope tag, were sequence-veriﬁed and expressed in the
vector pcDNA3.1.
2.4. Immunoﬂuorescence
Cells were transfected with DNA encoding one of the four
HA-tagged uromodulin constructs (above). Cells were ﬁxed,
permeabilized and incubated with mouse monoclonal anti-HA
primary antibody (Covance, HA.11 clone 16B12), followed by
Cy3-conjugated goat anti-mouse secondary antibody. For double
immunoﬂuorescence experiments, uromodulin was detected using
a rabbit polyclonal anti-HA antibody (Sigma), followed by a
Cy3-conjugated goat anti-rabbit antibody (Sigma), and calnexin
was detected using a mouse monoclonal antibody (Abcam,
AF-18), followed by a ﬂuorescein isothiocyanate-conjugated goat
anti-mouse secondary antibody (Sigma). Cells were imaged by
confocal laser scanning microscopy.
2.5. Isolation of epitope-tagged proteins
Using calcium phosphate precipitation, tsA 201 cells were
transfected with 250 lg of DNA for 5  162 cm2 ﬂasks and incu-
bated for 48 h at 37 C to allow protein expression. Supernatant
culture media were harvested, and cells were solubilized in 1%
(v/v) Triton X-100 for 1 h at 4 C. Samples were analyzed by immu-
noblotting using a mouse monoclonal anti-b-actin antibody
(Sigma, clone AC-15). Both media and cell extracts were centri-
fuged at 62000g to remove all insoluble material. Clariﬁed super-
natants were incubated with anti-HA-agarose beads (Sigma) for
3 h. Beads were washed extensively and bound protein eluted with
HA peptide (100 lg/ml). Eluted samples were analyzed by
SDS–PAGE, followed by either immunoblotting using a mouse
monoclonal anti-HA antibody, or Coomassie blue staining.Fig. 1. Isolation and AFM imaging of uromodulin from human urine. (A) Healthy v
immunoblotting showed a major band at the expected molecular mass for uromodulin
consisted almost entirely of uromodulin. (C) A typical low-magniﬁcation AFM image of
(arrowheads). (D) High-magniﬁcation AFM image.2.6. AFM imaging
Protein samples were diluted to a ﬁnal concentration of
0.04 nM, and 45 ll of each sample was adsorbed to freshly cleaved
mica disks for 5 min, followed by washing with Biotechnology Per-
formance Certiﬁed-grade water (Sigma) and drying under nitrogen.
Imaging was performed with a Veeco Digital Instruments
Multimode atomic force microscope controlled by a Nanoscope IIIa
controller. Samples were imaged in air, using tapping mode. The
silicon cantilevers used had a drive frequency 300 kHz and a
speciﬁed spring constant of 40 N/m (Olympus). The applied
imaging force was kept as low as possible (As/A0  0.85). Fibrous
structures were quantiﬁed using Scanning Probe Image Processor
version 5 (Image Metrology).
2.7. Patients and clinical investigations
A diagnostic renal biopsy was obtained from the index case and
processed for electron microscopy (EM) by standard methods.
Genomic DNA from Kindred B was sequenced according to
standard methods.
3. Results and discussion
Urine from a healthy volunteer was ﬁrst analyzed by SDS–PAGE,
followed by Coomassie blue staining or immunoblotting using an
anti-uromodulin antibody. In both cases a major band was seen
at 95kDa (Fig. 1A), conﬁrming the presence of uromodulin. Cen-
trifugation of urine at 10000g for 10 min has been shown to pel-
let uromodulin [13]. As shown in Fig. 1B, the resuspended pellet
contained uromodulin at an increased concentration and purity
relative to the crude urine sample. Similar results were obtained
with two additional healthy volunteers. The resuspended sample
was imaged using AFM. Images showed the presence of large con-
voluted ﬁbrous structures (Fig. 1C and D), and occasional circular
features (arrowheads, Fig. 1C). Given that the uromodulin sample
was essentially pure, we are conﬁdent that the ﬁbrous structures
do indeed represent uromodulin. Imaging of urine from a patient
with FJHN caused by the Indel mutation revealed no obvious differ-
ences compared with WT, likely because of the presence of WT
protein in the heterozygous condition (data not shown).
The index case in Kindred B (Fig. 2A) is a 35 year-old male who
developed biochemical evidence of CKD at age 24 years. At that
time he was hyperuricemic and suffering from recurrent gout,
and allopurinol was commenced. Hypertension developed at age
25 years. His brother is currently under investigation for hyperuri-
cemia with reduced urinary urate excretion, which is associated
with UMOD nephropathy [4]. Their mother had pre-eclampsia
during her ﬁrst pregnancy. She also had CKD and hypertension
since age 34 years; a recent estimated glomerular ﬁltration rateolunteer urine analyzed by SDS–PAGE followed by Coomassie blue staining or
(95kDa). Molecular mass markers (kDa) are shown. (B) Pelleted urinary protein
this uromodulin revealed large ﬁbrous structures and occasional circular features
Fig. 2. Features of Kindred B. (A) Pedigree showing multi-generation history of renal disease (index case arrowed). Squares and circles denote males and females, respectively.
White, black and gray symbols denote affected, unaffected and unknown status. , genetically conﬁrmed. (B) The lower sequence shows WT UMOD, and the upper sequence
shows the C155R heterozygote, with the predicted amino acids indicated above. (C) Electron micrographs of a renal biopsy taken from the index case, showing marked
protein accumulation in the ER and unstacking of Golgi cisternae (examples denoted by asterisks).
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developed end-stage renal failure and died of complications of
renal transplantation. Both the proband and his mother were found
by direct genomic DNA sequencing to harbor the same heterozy-
gous missense mutation (C155R) in UMOD (Fig. 2B). This is
predicted to affect protein folding since (in common with most
other reported mutations) it removes a cysteine residue [14]. No
other potentially pathogenic sequence alterations were identiﬁed.
Most patients with uromodulin nephropathy present with
already-shrunken kidneys due to the progressive ﬁbrotic process
associated with the disorders, and as a consequence, renal biopsies
are not performed. However, the C155R index patient has had a
biopsy, which we were able to process for EM. Electron micro-
graphs (Fig. 2C) show extensive accumulations of protein within
the ER, and apparent unstacking and dilatation of the Golgi cister-
nae, indicating a severe intracellular trafﬁcking defect with this
UMOD mutant.
In order to study UMOD mutants in the absence of WT protein,
constructs of WT, Indel, C155R and C150S uromodulin, each bear-
ing an N-terminal HA tag, were generated. Note that Indel [8] is
associated with a milder biochemical phenotype than the C155R
or C150S [12] phenotypes. The four constructs were each tran-
siently expressed in tsA 201 cells. Transfected cells were ﬁxed, per-
meabilized and subjected to immunoﬂuorescence analysis (Fig. 3A,
upper panels). The majority of the WT protein was located at the
plasma membrane. In contrast, C150S had a predominantly intra-
cellular distribution, with clear accumulations of the protein inside
the cell, rather than a diffuse reticular pattern. The Indel construct
was of intermediate appearance, with reduced membrane staining
and an increased intracellular signal, as previously demonstrated
[8]. The novel C155R mutation had a staining pattern very similar
to C150S, consistent with its severe phenotype in vivo, and also
with the EM data. Higher-magniﬁcation images of intracellularcompartments harboring the C150S mutant are shown in the lower
panels (Fig. 3A). The staining pattern for the C150S mutant was
compared with that for the recognized ER marker calnexin [15].
As can be seen (Fig. 3B), the immunoﬂuorescence signals for the
two proteins overlapped extensively, consistent with accumulation
of C150S uromodulin in the ER.
Uromodulin was puriﬁed from either culture media of cells
expressing the various constructs, or from Triton X-100-solubilized
cell extracts, by anti-HA immunoafﬁnity chromatography. Identi-
cal conditions (i.e., volumes, dilutions, etc.) were used in each case,
to permit direct comparisons of the extents of processing and
secretion of the four forms of the protein. Immunoblotting of the
Triton X-100 cell extracts for b-actin conﬁrmed that equal amounts
of protein were used as the starting material for the four puriﬁca-
tions (Fig. 3C, top panel). Immunoblotting of equivalent samples of
puriﬁed secreted protein with an anti-HA antibody showed a single
band at 95kDa, representing the mature, fully processed form of
the protein (Fig. 3C, center-left panel). Notably, there was a pro-
gressive decrease in the quantity of secreted protein that corre-
lated with the severity of the mutation; Coomassie blue staining
conﬁrmed this observation (Fig. 3C, bottom-left panel). Immuno-
blotting of the cellular protein revealed two bands at 95kDa
and 85kDa, representing the mature, fully processed form seen
in culture media and a smaller immature form, respectively
(Fig. 3C, right panels) [8]. There was an increase in the proportion
of immature protein with the mutants, particularly C155R and
C150S, consistent with the intracellular retention proﬁle reported
above.
Uromodulin samples puriﬁed from the transfected tsA 201 cell
supernatants and cell extracts were subjected to AFM imaging, and
structural components quantiﬁed. Numerous ﬁbrous structures
were seen in the secreted WT sample (Fig. 4A). These were smaller
and less convoluted than those found in urine, possibly because
Fig. 3. Analysis of uromodulin trafﬁcking and processing in transiently transfected tsA 201 cells. (A) WT protein was mostly at the plasma membrane (upper panels), while
the mutants showed intracellular retention correlating with phenotypic severity. Zoomed images of intracellular aggregations seen in cells expressing C150S uromodulin are
shown in the lower panels. (B) Immunoﬂuorescence signals for C150S uromodulin and calnexin overlapped extensively, showing that the mutant uromodulin was
predominantly localized in the ER. (C) Immunoblotting for b-actin showed that equal amounts of protein were present in the starting material for the four uromodulin
puriﬁcations (top). HA-tagged uromodulin (WT, Indel, C155R and C150S) isolated from cell culture media (left) was composed of mature, fully processed uromodulin at
95kDa, whereas detergent extracts of transfected cells (right) showed an additional 85kDa band, representing immature protein.
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the protein was isolated by binding to and elution from immun-
obeads. Signiﬁcantly, despite lower secreted amounts, imaging of
secreted samples from cells expressing the three uromodulinmutants showed no evidence of a structural abnormality, as similar
ﬁbrous structures were present in all three cases. This result
demonstrates that while the three mutations cause intracellular
protein retention, any protein that is secreted adopts a very similar
Fig. 4. AFM imaging of secreted and intracellular uromodulin. Zoomed images of
typical ﬁbrillar uromodulin structures seen for WT and mutants in cell culture
media (A) and for mutants alone in cell extracts (B), indicating premature
intracellular ﬁbril assembly for the mutant proteins.
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100 images) were seen in samples of puriﬁed intracellular WT
uromodulin, indicating that polymerization normally occurs
post-secretion. In marked contrast, all three mutant forms of
uromodulin isolated from cell extracts contained numerous ﬁbrous
structures (Fig. 4B). Speciﬁcally, in 100 AFM images, the numbers
of these structures were: 156 (Indel), 122 (C155R), and 110
(C150S). Hence, all three mutations cause abnormal, premature
intracellular polymerization of uromodulin.
Our data suggest that UMOD-associated disease bears similari-
ties to other intracellular protein aggregation disorders such as
a1-antitrypsin deﬁciency [16] and Parkinson’s disease [17]. By
analogy, chronic renal damage in patients carrying mutant UMOD
could be explained by the activation of ER stress, overloaded or
unfolded protein pathways, as described for these other conditions
[18]. In conclusion, this study provides the ﬁrst evidence that
UMOD diseases result from inappropriate intracellular protein
polymerization.
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